Skip to Search
Skip to Navigation
Skip to Main Content
Skip to Footer
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Login
Google Translate
Select language
English
French
Spanish
Login
Username
*
Password
*
Staff Login
×
Google Translate
Select language
English
French
Spanish
Login
Menu
Site Search
Search Options
Resources
Everything
Advanced Search
Uptodate
All
Title Search
Author
Patients & Caregivers
Healthcare Providers
Researchers & Partners
Investors
menu
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Google News
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Biotech Collapses 19% After Biogen-Tied Essential Tremor Drug Fails - Investor's Business Daily
Sage halts second trial this year, this time in essential tremor, after study failure - The Business Journals
Sage Therapeutics Stock Slides as Pipeline Thins - Barron's
Sage Therapeutics Stock Slides as Pipeline Thins - Barron's
Sage Therapeutics (NASDAQ:SAGE) Earns “Hold” Rating from Needham & Company LLC - Defense World
When the Price of (SAGE) Talks, People Listen - Stock Traders Daily
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Biogen, Sage Scrap Essential Tremor Study After Phase II Failure - BioSpace
Biogen, Sage Scrap Essential Tremor Study After Phase II Failure - BioSpace
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
next ›
last »
×